Cefmenoxime is a new semisynthetic cephalosporin with a broad spectrum of activity against many gram-positive and gram-negative bacteria and excellent beta-lactamase stability (10, 16) . Studies on subjects with normal renal function have shown that the drug is primarily eliminated unchanged in the urine (7) . Renal insufficiency is, therefore, expected to prolong the elimination of cefmenoxime, and this study was conducted to examine the pharmacokinetics of this antibiotic in patients with various degrees of renal insufficiency and to determine the influence of hemodialysis on its elimination.
MATERIALS AND METHODS Antibiotic. Cefmenoxime was supplied by Takeda Chemical Industries Ltd., Osaka, Japan.
Subjects. Twenty-four adult male and female subjects with renal function ranging from normal to anephric were studied after informed consent was obtained. Endogenous creatinine clearance (CLCR) was determined by collecting urine over 24-h period. The subjects were divided into four groups according to their renal function: group 1, CLCR of greater than 85 ml/min per 1.73 M2; group 2, CLCR of 50 to 85 ml/min per 1.73 M2; group 3, CLCR of 10 to 50 ml/min per 1.73 mi2; and group 4, CLCR of less than 10 ml/min per 1.73 M2. All six subjects in group 4 were receiving maintenance hemodialysis for end-stage renal failure.
Procedure. Each subject received 1.0 g of cefmenoxime dissolved in 20 ml of physiological saline intravenously over exactly 5 min. Blood samples for serum cefmenoxime levels were obtained 10, 20, and 30 min and 1, 2, 4, 6, 12, and 24 h after injection. Urine samples were collected during time intervals of 0 to 2 h, 2 to 6 h, and 6 to 24 h postdosing. Serum and urine samples were stored at -70°C until assayed.
The six hemodialysis patients in group 4 were studied on two separate occasions, i.e., during and between hemodialysis. The interdialysis period study followed the same protocol as used in other patients not receiving hemodialysis. The study during the hemodialysis session consisted of injection of cefmenoxime into the venous return of the dialyzer over 5 min at the start of dialysis followed by collection of blood samples from the blood inlet and outlet of the dialyzer for determination of the drug concentration at 30 min and 1, 2, and 4 h after injection of the drug and also at the termination of the dialysis procedure. Cefmenoxime concentration was also determined on the pooled dialysate outflow fluid. The dialyzer used was RENEK-1A 10M (Kuraray Co., Ltd., Osaka, Japan), a hollow-fiber dialyzer with a surface area of 1.0 M2. Each subject was dialyzed for 5 h with a dialysate fluid flow rate of 500 ml/min and a blood flow rate of 200 ml/min.
Assay. Cefmenoxime concentrations in serum, urine, and dialysate fluid were determined by the cylinder-plate technique with Escherichia coli NIHJ JC-2 as the test organism grown in DST agar medium, pH 7.4 (Oxoid Ltd., London, England) (5). Standards for serum samples were prepared in Monitrol I (American Hospital Supply Co.), while urine and dialysate standards were made with 0.1 M phosphate buffer, pH 7.4. A concentration of cefmenoxime as low as 0.1 jig/ml could be measured by this method. The within-day coefficients of variation were 3.3 and 2.3% for the low and high assay extremes, respectively, whereas the between-day coefficients of variation were 7.8 and 9.0%, respectively.
Pharmacokinetic analysis. The serum cefmenoxime levels after intravenous administration were described in terms of a two-compartment open model, and the individual serum level profiles were fitted to a biexponential function of the form: C = A x e-a' + B x e-t, in which C is the concentration of antibiotic in serum at time t postdosing; a and 1 are the rate constants governing the distribution and elimination phases of drug loss from serum, respectively; and A and B are the intercepts of slopes a and P with the ordinate. Pharmacokinetic analysis was performed with a nonlinear least-squares program developed by Yamaoka et al. (17) (7), although a somewhat longer tY2p, has been reported by others for healthy subjects (4, 6, 12, 14) . Thus, the t12, of cefmenoxime after intravenous dosing in subjects with normal renal function is comparable to that of cefotax- ime (0.9 to 1.2 h), but is shorter than those of other cephalosporins (1, 8) . The mean t1/2p increased with a decrease in renal function (Table 3) , and this is similar to the case with other cephalosporins with the notable exceptions of ceftriaxone, cefoperazone, and cefpiramide (1, 11) .
In patients with reduced renal function, the widely recommended modification of the dose schedule is to prolong the dosage interval, multiplying it by 13n/lrf, 13n and 13f being the elimination rate constants in normal subjects and in those with renal failure, respectively (2, 3) . A significant positive correlation existed between P and CLCR (r = 0.891, p < 0.01), and ,B of cefmenoxime may be predicted by the equation: 1B (hour-') = 0.00837 x CLCR (ml/min per 1.73 m2) + 0.0469 (Fig. 3) . Thus, assuming that the standard individual dose schedule of cefmenoxime in subjects with normal renal function is 1.0 g intravenously every 6 h, the same standard individual dose may be given every 8 h for those with a CLCR of 60 ml/min per 1.73 m2, every 12 h for those with CLCR of 50 ml/min per 1.73 m2, and every 24 h for those with CLCR of 20 ml/min per 1.73 i2. Application of the same rule to those patients with severe renal failure would be rather inappropriate since it is expected to produce a drug level in-serum that is too low over a prolonged time. It is suggested instead that 1.0 g be administered every 24 h to those with a CLCR of 10 ml/min per 1.73 m2 and that 0.75 g be administered every 24 h to functionally anephric subjects.
The average hemodialysis clearance (CLHD) of cefmenoxime can be calculated either as the difference between the serutn clearances of the drug during and between hemodialysis in the same patient or alternatively by the equation CLHD = X/AU Co,, where X is the total amount of the drug recovered in the pooled dialysate outflow fluid, t is the duration of dialysis, and AUCO, is the AUC from time zero to t. CLHD as calculated by the former method averaged 20.4 + 12.8 ml/min (Table 4 ) and was 24.6 + 8.7 ml/min by the latter method.
The proportion of the body pool of drug removed by a given period of hemodialysis (f) is calculated by the equation: f = [CLHD/(CLHD + CLb)] {1 -exp [-(CLHD + CLb)t/Vd)I}, where CLHD is the hemodialysis clearance of the drug, CLb.is the intrinsic body clearance of the drug, and t is the duration of hemodialysis (9, 15) . In a hypothetical anephric patient with a body weight of 60 kg, the Varca is expected to be 16.2 liters (i.e., 0.270 liters/kg) and v is 0.0469/h (Fig. 3) . The intrinsic body clearance' of cefmenoxime (CLb) in this patient is: CLb = Varea X a = 12.7 ml/min. Assuming that the hemodialysis clearance of cefmenoxime is 20.4 ml/min (Table 4) , f is calculated to be 0.282 when the duration of the dialysis is 5 h. Thus, a standard 5-h hemodialysis is expected to remove 28.2% of the amount of the drug present in the body at the start of dialysis. Theoretically, at least, this amount of the drug should be supplemented at the end of hemodialysis, although whether such a maneuver is necessary should be decided on clinical grounds in individual cases.
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